Gyre Therapeutics (NASDAQ:GYRE) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Gyre Therapeutics (NASDAQ:GYRE) from a strong sell rating to a hold rating in a report released on Monday morning,Zacks.com reports.

GYRE has been the topic of several other reports. Weiss Ratings downgraded shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Stock Down 3.4%

Shares of NASDAQ GYRE opened at $7.01 on Monday. Gyre Therapeutics has a 52 week low of $5.44 and a 52 week high of $9.42. The business’s 50 day moving average price is $6.52 and its 200 day moving average price is $7.25. The firm has a market cap of $781.54 million, a P/E ratio of -77.88 and a beta of 1.89.

Insider Buying and Selling

In other news, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00. Following the sale, the chief operating officer owned 700,000 shares of the company’s stock, valued at $4,305,000. This trade represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the transaction, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. This trade represents a 0.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 32,535 shares of company stock worth $219,580 in the last ninety days. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Gyre Therapeutics by 28.6% in the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after purchasing an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after buying an additional 45,772 shares during the period. Millennium Management LLC acquired a new position in shares of Gyre Therapeutics during the 3rd quarter worth approximately $267,000. State Street Corp lifted its position in shares of Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after buying an additional 19,472 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in Gyre Therapeutics in the 3rd quarter valued at $111,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.